Galena Biopharma Inc (GALE.OQ) Quote| Reuters.com
Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
29 Jun 2016
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
361,123
52-wk High
$2.49
52-wk Low
$0.59

GALE.OQ

Chart for GALE.OQ

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $63.64
Shares Outstanding(Mil.): 181.84
Dividend: --
Yield (%): --

Financials

  GALE.OQ Industry Sector
P/E (TTM): -- 33.67 34.69
EPS (TTM): -0.26 -- --
ROI: -88.58 14.91 14.13
ROE: -122.39 15.99 15.35

BRIEF-Galena Biopharma's GALE-301 well-tolerated based on primary analysis

* Galena Biopharma presents GALE-301 phase 1/2a primary analysis at the American Society Of Clinical Oncology Annual Meeting 2016

Jun 06 2016

BRIEF-Galena Biopharma receives fast track designation for Neuvax(tm)

* Receives fast track designation for neuvax(tm) (nelipepimut-s) present clinical trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 01 2016

BRIEF-Galena Biopharma say it raised $24 mln in debt, option financing

* Galena Biopharma files to say it raised $24 million in debt financing and that related to option, warrants - SEC filing Source text: http://1.usa.gov/1WQlNcY Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

May 24 2016

BRIEF-Rxi Pharmaceuticals reports Q1 loss of $0.34 per share

* Believes existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year

May 12 2016

BRIEF-Galena Biopharma reports Q1 loss per share $0.90

* Galena Biopharma reports first quarter 2016 financial results and provides a corporate update

May 10 2016

BRIEF-Rxi Pharmaceuticals explores strategic options including range of potential M&A

* Is in process of exploring strategic options including a range of potential M&A and business development opportunities

May 10 2016

BRIEF-RXI Pharmaceuticals says received notice of allowance for RXI-109 from USPTO

* RXI Pharmaceuticals says fortifies its novel RNAi patent portfolio with notice of allowance for lead clinical candidate RXI-109 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 19 2016

BRIEF-RXI Pharmaceuticals says reverse stock split of shares at a ratio of 1-for-10

* Announced a reverse stock split of its shares of common stock at a ratio of 1-for-10

Apr 15 2016

BRIEF-Rxi Pharmaceuticals reports Q4 loss per share of $0.04

* Rxi pharmaceuticals reports fourth quarter and year end 2015 financial results and recent corporate highlights

Mar 30 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.